The Polish Competition Authority fines € 457.000 a pharmaceutical company and its distributor for price fixing and supply limiting agreements (Johnson & Johnson - COMPOL)

Johnson & Johnson Poland, member of the worldwide group of producing, import-exporting and selling of pharmaceuticals, is in charge of the distribution in Poland of a Swiss made medicine, Eprex. This medicine is used in the treatment of anemia provoked by an insufficient level of erythropoietin (EPO), which is a growth factor glycoprotein hormone for erythrocyte (red blood cell) precursors in human bone marrow that increases the number of the red blood cells. Johnson & Johnson Poland had concluded a distribution agreement with COMPOL to distribute Eprex. The distribution agreement provided that the distributor was allowed to sell Eprex only at prices established together with Johnson & Johnson Poland and only to clients indicated in the annex of the agreement. The

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • French National Research Agency - ANR (Paris)
  • Orrick, Herrington & Sutcliffe (Washington)

Quotation

Joanna Faruga, Veronika Metonidze, The Polish Competition Authority fines € 457.000 a pharmaceutical company and its distributor for price fixing and supply limiting agreements (Johnson & Johnson - COMPOL), 28 May 2004, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 21

Visites 7875

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues